2024 Q2 Form 10-Q Financial Statement
#000121390024045020 Filed on May 20, 2024
Income Statement
Concept | 2024 Q2 | 2024 Q1 |
---|
Balance Sheet
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $1.390K | |
YoY Change | -37.39% | |
Cash & Equivalents | $1.392K | |
Short-Term Investments | ||
Other Short-Term Assets | $47.22K | |
YoY Change | -5.71% | |
Inventory | ||
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $48.61K | |
YoY Change | -7.06% | |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | ||
YoY Change | ||
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | ||
YoY Change | ||
Total Long-Term Assets | $4.00 | |
YoY Change | -300.0% | |
TOTAL ASSETS | ||
Total Short-Term Assets | $48.61K | |
Total Long-Term Assets | $4.00 | |
Total Assets | $48.61K | |
YoY Change | -7.04% | |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.925M | |
YoY Change | 13.06% | |
Accrued Expenses | ||
YoY Change | ||
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $96.24K | |
YoY Change | 197.13% | |
Long-Term Debt Due | $207.7K | |
YoY Change | 10.48% | |
Total Short-Term Liabilities | $2.230M | |
YoY Change | 16.01% | |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | |
YoY Change | ||
Other Long-Term Liabilities | ||
YoY Change | ||
Total Long-Term Liabilities | $0.00 | |
YoY Change | ||
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $2.230M | |
Total Long-Term Liabilities | $0.00 | |
Total Liabilities | $2.230M | |
YoY Change | 16.01% | |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$28.91M | |
YoY Change | 1.43% | |
Common Stock | $771.8K | |
YoY Change | 0.0% | |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | -$2.182M | |
YoY Change | ||
Total Liabilities & Shareholders Equity | $48.61K | |
YoY Change | -7.04% |
Cashflow Statement
Concept | 2024 Q2 | 2024 Q1 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | ||
CY2023Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
CY2023Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
shares | |
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-03-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
333-191083 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
ACTAVIA LIFE SCIENCES, INC. | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
39-2080103 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
5 Penn Plaza | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
19th Floor, # 1954 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
New York | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NY | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
10001 | ||
dei |
City Area Code
CityAreaCode
|
(646) | ||
dei |
Local Phone Number
LocalPhoneNumber
|
396-4087 | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
771811360 | shares |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1392 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
74986 | usd |
CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
47222 | usd |
CY2023Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
20671 | usd |
CY2024Q1 | us-gaap |
Assets
Assets
|
48614 | usd |
CY2023Q3 | us-gaap |
Assets
Assets
|
95657 | usd |
CY2024Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1503658 | usd |
CY2023Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1458216 | usd |
CY2024Q1 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
53950 | usd |
CY2023Q3 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
8509 | usd |
CY2024Q1 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
42294 | usd |
CY2023Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
4730 | usd |
CY2024Q1 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
1862 | usd |
CY2023Q3 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
2036 | usd |
CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2230363 | usd |
CY2023Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2051566 | usd |
CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
CY2023Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1500000000 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1500000000 | shares |
CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
771811360 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
771811360 | shares |
CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
771811360 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
771811360 | shares |
CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
771811 | usd |
CY2023Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
771811 | usd |
CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
25953197 | usd |
CY2023Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
25935882 | usd |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-28906757 | usd |
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-28663602 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2181749 | usd |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1955909 | usd |
CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
48614 | usd |
CY2023Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
95657 | usd |
CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
60161 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
93955 | usd |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
166374 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
198811 | usd | |
CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11226 | usd |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13704 | usd |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
29743 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
31660 | usd | |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3858793 | usd |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3858793 | usd | |
CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
71387 | usd |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
3966452 | usd |
us-gaap |
Operating Expenses
OperatingExpenses
|
196117 | usd | |
us-gaap |
Operating Expenses
OperatingExpenses
|
4089264 | usd | |
CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-71387 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3966452 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-196117 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4089264 | usd | |
CY2024Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
15837 | usd |
CY2023Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
164147 | usd |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
30697 | usd | |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
180333 | usd | |
CY2024Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
8743 | usd |
CY2023Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
6489 | usd |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
17200 | usd | |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
18191 | usd | |
CY2024Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
449 | usd |
CY2023Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
7888 | usd |
us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
859 | usd | |
us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
8744 | usd | |
CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-24131 | usd |
CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-162748 | usd |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-47038 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-189780 | usd | |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-95518 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4129200 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-243155 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-4279044 | usd | |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0 | ||
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
771811360 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
588518916 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
771811360 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
384249138 | shares | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2103546 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
17315 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-95518 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2181749 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1809641 | usd |
CY2023Q1 | rasp |
Issuance Of Stock For The Conversion Of Promissory Notes
IssuanceOfStockForTheConversionOfPromissoryNotes
|
209773 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
3858793 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4129200 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1870275 | usd |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1955909 | usd |
us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
17315 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-243155 | usd | |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2181749 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1688597 | usd |
rasp |
Issuance Of Stock For The Conversion Of Promissory Notes
IssuanceOfStockForTheConversionOfPromissoryNotes
|
209773 | usd | |
us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
3858793 | usd | |
us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
28800 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-4279044 | usd | |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1870275 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-243155 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-4279044 | usd | |
us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
16849 | usd | |
us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
18191 | usd | |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
30697 | usd | |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
180333 | usd | |
us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
859 | usd | |
us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
8744 | usd | |
rasp |
Common Stock Issued For Services
CommonStockIssuedForServices
|
3858793 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
45442 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
113932 | usd | |
us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
40542 | usd | |
us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
41596 | usd | |
us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
-27399 | usd | |
us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
-49786 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-83085 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-25157 | usd | |
us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
18000 | usd | |
us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
30000 | usd | |
rasp |
Payments On Note Payable
PaymentsOnNotePayable
|
8509 | usd | |
rasp |
Payments On Note Payable
PaymentsOnNotePayable
|
41985 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
9491 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-11985 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-73594 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-37142 | usd | |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
74986 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
39363 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1392 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2221 | usd |
rasp |
Derivative Liabilities In Connection With Issuance Of Convertible Notes
DerivativeLiabilitiesInConnectionWithIssuanceOfConvertibleNotes
|
685 | usd | |
rasp |
Derivative Liabilities In Connection With Issuance Of Convertible Notes
DerivativeLiabilitiesInConnectionWithIssuanceOfConvertibleNotes
|
1200 | usd | |
rasp |
Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
|
17315 | usd | |
rasp |
Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
|
28800 | usd | |
rasp |
Issuance Of Common Stock For Conversions Of Promissory Notes
IssuanceOfCommonStockForConversionsOfPromissoryNotes
|
209773 | usd | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
108099001 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2865176 | shares | |
CY2023Q1 | us-gaap |
Deferred Discounts Finance Charges And Interest Included In Receivables
DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
|
1187 | usd |
CY2023Q1 | us-gaap |
Payments For Fees
PaymentsForFees
|
4626 | usd |
CY2023Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
236 | usd |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. GENERAL INFORMATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actavia Life Sciences, Inc. (f/k/a Rasna Therapeutics, Inc. the “Company”) is a biotechnology company incorporated in the State of Delaware on March 28, 2016. The Company is engaged in modulating the molecular target LSD1, which is implicated in the disease progression of leukemia and lymphoma. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited condensed consolidated financial statements are presented in United States dollars (“USD”) which is also the functional currency of the primary economic environment in which the Company operates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management continues to evaluate the impact of inflation and the economic environment on the Company, and has concluded that while it is reasonably possible that inflation could have a negative effect on the Company’s financial position, results of its operations and/or ability to secure additional cash resources, there is no current impact as cash resources are currently secured by existing shareholders. The financial statements do not include any adjustments that might result from this uncertainty.</p> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations.</p> | ||
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-28906757 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-243155 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-83085 | usd | |
CY2024Q1 | us-gaap |
Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
|
18000 | usd |
CY2024Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
0.001 | |
CY2024Q1 | us-gaap |
Deferred Finance Costs Gross
DeferredFinanceCostsGross
|
1000000 | usd |
CY2024Q1 | us-gaap |
Investment Interest Rate
InvestmentInterestRate
|
0.02 | pure |
CY2024Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
685 | usd |
us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
685 | usd | |
CY2023Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
7888 | usd |
us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
8744 | usd | |
CY2023Q4 | rasp |
Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
|
17315 | usd |
CY2023Q1 | rasp |
Beneficial Conversions Feature Related To Issuance Of Convertible Notes
BeneficialConversionsFeatureRelatedToIssuanceOfConvertibleNotes
|
28800 | usd |
CY2024Q1 | us-gaap |
Funds Held Under Reinsurance Agreements Asset
FundsHeldUnderReinsuranceAgreementsAsset
|
53950 | usd |
CY2024Q1 | us-gaap |
Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
|
13500 | usd |
CY2024Q1 | us-gaap |
Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
|
0.0799 | pure |
CY2024Q1 | us-gaap |
Deferred Discounts Finance Charges And Interest Included In Receivables
DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
|
1359 | usd |
CY2024Q1 | us-gaap |
Payments For Fees
PaymentsForFees
|
4645 | usd |
CY2024Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
270 | usd |
CY2023Q1 | us-gaap |
Funds Held Under Reinsurance Agreements Asset
FundsHeldUnderReinsuranceAgreementsAsset
|
53950 | usd |
CY2023Q1 | us-gaap |
Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
|
13500 | usd |
CY2023Q1 | us-gaap |
Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
|
0.0699 | pure |
CY2024Q1 | us-gaap |
Compensating Balance Amount
CompensatingBalanceAmount
|
175000 | usd |
CY2023Q3 | us-gaap |
Compensating Balance Amount
CompensatingBalanceAmount
|
175000 | usd |
CY2024Q1 | us-gaap |
Cash And Due From Banks
CashAndDueFromBanks
|
87360 | usd |
CY2020Q1 | us-gaap |
Loans Payable
LoansPayable
|
65000 | usd |
CY2020Q2 | us-gaap |
Loans Payable
LoansPayable
|
7000 | usd |
CY2020Q2 | us-gaap |
Other Loans Payable
OtherLoansPayable
|
72000 | usd |
CY2024Q1 | us-gaap |
Loans Payable
LoansPayable
|
95040 | usd |
CY2023Q3 | us-gaap |
Notes And Loans Payable
NotesAndLoansPayable
|
93600 | usd |
CY2022Q3 | us-gaap |
Loans Payable
LoansPayable
|
85000 | usd |
CY2024Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2023Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
shares | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
shares | |
CY2023Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
shares | |
CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
usd | ||
CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | ||
CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.00 | |
CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.00 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.00 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.00 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
384249138 | shares | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
588518916 | shares |
CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
771811360 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
771811360 | shares | |
rasp |
Common Stock Issued For Services
CommonStockIssuedForServices
|
usd | ||
rasp |
Issuance Of Common Stock For Conversions Of Promissory Notes
IssuanceOfCommonStockForConversionsOfPromissoryNotes
|
usd | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--09-30 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001582249 |